Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity

ACS Medicinal Chemistry Letters

Volumn 1, Issue 9, 2010, Pages 483-487

  Xue, Chu Biao ^a   Chen, Lihua ^a   Cao, Ganfeng ^a   Zhang, Ke ^a   Wang, Anlai ^a   Meloni, David ^a   Glenn, Joseph ^a   Anand, Rajan ^a   Xia, Michael ^a   Kong, Ling ^a   Huang, Taisheng ^a   Feng, Hao ^a   Zheng, Changsheng ^a   Li, Mei ^a   Galya, Laurine ^a   Zhou, Jiacheng ^a   Shin, Niu ^a   Baribaud, Fredric ^a   Solomon, Kim ^a   Scherle, Peggy ^a   Zhao, Bitao ^a   Diamond, Sharon ^a   Emm, Tom ^a   Keller, Douglas ^a   Contel, Nancy ^a   Yeleswaram, Swamy ^a   Vaddi, Kris ^a   Hollis, Gregory ^a   Newton, Robert ^a   Friedman, Steven ^a   Metcalf, Brian ^a   more..

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

antagonist; antiviral; CCR5; coreceptor; HIV 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INCB 9471; INDAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650185021     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml1001536     Document Type: Article

References (16)

1. Samson, M.; Labbe, O.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene Biochemistry 1996, 35, 3362-3367
2. Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1 Science 1996, 272, 1955-1958
3. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; DiMarzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Littman, D.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1 Nature 1996, 381, 661-666
4. + cells is mediated by the chemokine receptor CC CKR-5 Nature 1996, 381, 667-673
5. Liu, R.; Paxton, W. A.; Choe, S.; Ceradini, D.; Martin, S. R.; Horuk, R.; Macdonald, M. E.; Stuhlmann, H.; Koup, R. A.; Landau, N. R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection Cell 1996, 86, 367-377
6. Michael, N. L.; Chang, G.; Louie, L. G.; Mascola, J. R.; Dondero, D.; Birx, D. L.; Sheppard, H. W. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression Nat. Med. 1997, 3, 338-340
7. Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety J. Med. Chem. 2000, 43, 2049-2063
8. Palani, A.; Tagat, J. R. Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists J. Med. Chem. 2006, 49, 2851-2867
9. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Prog. Med. Chem. 2005, 43, 239-271
10. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type-I activity Antimicrob. Agents Chemother. 2005, 49, 4721-4732
11. Turner, J. E.; Steinmetz, O. M.; Stahl, R. A.; Panzer, U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases Mini-Rev. Med. Chem. 2007, 7, 1089-1096
12. Vierboom, M. P.; Zavodny, P. J.; Chou, C. C.; Tagat, J. R.; Pugliese-Sivo, C.; Strizki, J.; Steensma, R. W.; McCombie, S. W.; Celebi-Paul, L.; Remarque, E.; Jonker, M.; Narula, S. K.; Hart, B. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5 Arthritis Rheum. 2005, 52, 627-636
13. Tagat, J. R.; McCombie, S. W.; Nazareno, D.; Labroli, M. A.; Xiao, Y.; Steensma, R. W.; Strizki, J. M.; Baroudy, B. M.; Cox, K.; Lachowicz, J.; Varty, G.; Watkins, R. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV: Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4- (trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective and orally bioavailable CCR5 antagonist J. Med. Chem. 2004, 47, 2405-2408
14. Strizki, J. M.; Tremblay, C.; Xu, S.; Wojcki, L.; Wagner, N.; Gonsiorek, W.; Hipkin, W.; Chou, C.-C.; Pugliesie-Sivo, C.; Xiao, Y.; Tagat, J. R.; Cox, K.; Priestley, T.; Sorota, S.; Huang, W.; Hirsch, M.; Reyes, G. R.; Baroudy, B. M. Discovery and characterization of Vicriviroc (Sch-417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type-1 Antimicrob. Agents Chemother. 2005, 49, 4911-4919
15. Jacobsen, E. N.; Zhang, W.; Muci, A. R.; Ecker, J. R.; Deng, L. Highly enantioselective epoxidation catalysts derived from 1,2-diaminocyclohexane J. Am. Chem. Soc. 1991, 113, 7063-7064
16. Schürmann, D.; Fätkenheuer, G.; Reynes, J.; Michelet, C.; Raffi, F.; van Lier, J.; Caceres, M.; Keung, A.; Sansone-Parsons, A.; Dunkle, L. M.; Hoffmann, C. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults AIDS 2007, 21, 1293-1299